Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityNo recent work listed

Liang Zong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3330-4735; OpenAlex author ID A5077449611. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2015: 3 papers · 2016: 4 papers · 2017: 1 paper · 2018: 1 paper

Papers 9

  1. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions. Co-author DOI 10.1186/s13046-018-0740-4↗
  2. Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-β1 signaling in pancreatic cancer. Co-author DOI 10.1186/s13046-017-0655-5↗
  3. Reactive Oxygen Species and Targeted Therapy for Pancreatic Cancer. Co-author DOI 10.1155/2016/1616781↗
  4. The Relevance of Nrf2 Pathway and Autophagy in Pancreatic Cancer Cells upon Stimulation of Reactive Oxygen Species. Co-author DOI 10.1155/2016/3897250↗
  5. Hyperglycemia Promotes the Epithelial-Mesenchymal Transition of Pancreatic Cancer via Hydrogen Peroxide. Co-author DOI 10.1155/2016/5190314↗
  6. Lipoxin A4 Attenuates Cell Invasion by Inhibiting ROS/ERK/MMP Pathway in Pancreatic Cancer. Co-author DOI 10.1155/2016/6815727↗
  7. Resveratrol in the treatment of pancreatic cancer. First author DOI 10.1111/nyas.12837↗
  8. Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer. Co-author DOI 10.18632/oncotarget.3069↗
  9. miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. Co-author DOI 10.18632/oncotarget.3686↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 9 shared papers, 2015–2018 · strength 0.48
  2. Xuqi Li · 8 shared papers, 2015–2018 · strength 0.41
  3. Zhengdong Jiang · 7 shared papers, 2015–2018 · strength 0.39
  4. Jianjun Lei · 7 shared papers, 2015–2018 · strength 0.35
  5. Wanxing Duan · 7 shared papers, 2015–2018 · strength 0.35
  6. Qinhong Xu · 7 shared papers, 2015–2018 · strength 0.35
  7. Lun Zhang · 6 shared papers, 2015–2016 · strength 0.31
  8. Wei Li · 4 shared papers, 2016 · strength 0.22
  9. Jiguang Ma · 4 shared papers, 2015–2018 · strength 0.21
  10. Zheng Wang · 4 shared papers, 2015–2018 · strength 0.21
  11. Xin Chen · 3 shared papers, 2016–2018 · strength 0.18
  12. Tao Shan · 3 shared papers, 2016 · strength 0.15
  13. Ligang Nan · 3 shared papers, 2015–2016 · strength 0.14
  14. Zhenhua Ma · 3 shared papers, 2015–2016 · strength 0.14
  15. Cancan Zhou · 2 shared papers, 2017–2018 · strength 0.13
  16. Ke Chen · 2 shared papers, 2016–2018 · strength 0.12
  17. Jiahui Li · 2 shared papers, 2016 · strength 0.10
  18. Liang Han · 2 shared papers, 2015–2017 · strength 0.10
  19. Zheng Wu · 2 shared papers, 2015 · strength 0.08
  20. Liang Cheng · 1 shared paper, 2018 · strength 0.07
  21. Bin Yan · 1 shared paper, 2018 · strength 0.07
  22. Liankang Sun · 1 shared paper, 2017 · strength 0.06
  23. Hao Sun · 1 shared paper, 2016 · strength 0.05
  24. Xin Shen · 1 shared paper, 2016 · strength 0.05
  25. Pei Li · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.